New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
06:18 EDTRHHBYRoche acquires Genia Technologies for $125M in cash
Roche announced the acquisition of Genia Technologies, a privately held company, based in Mountain View, California. Genia is developing a single-molecule, semiconductor based, DNA sequencing platform using nanopore technology. Under the terms of the agreement, Roche will pay Genia’s shareholders $125M in cash. In addition to this payment from Roche, Genia’s shareholders may receive up to $225M in contingent payments depending on the achievement of certain milestones. Genia’s proprietary technology is expected to reduce the price of sequencing while increasing speed and sensitivity. Once the transaction is complete, Genia will be integrated into Roche Sequencing Unit and will continue to focus on the development of this innovative system.
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
09:25 EDTRHHBYRoche management to meet with JPMorgan
Meetings to be held in Jersey City/New York on December 1 and in Connectciut/New York on December 2 hosted by JPMorgan.
November 22, 2015
15:14 EDTRHHBYExelixis confirms Phase 3 data on Cotellic with Zelboraf for melanoma
Subscribe for More Information
15:09 EDTRHHBYGenentech reports data on Cotellic with Zelboraf for treatment of melanoma
Genentech, a member of the Roche Group, announced data from the pivotal coBRIM study, showing that Cotellic, or cobimetinib, in combination with Zelboraf, or vemurafenib, helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live "significantly longer" than with Zelboraf alone, according to the company. Cotellic plus Zelboraf reduced the risk of death by 30% compared to Zelboraf alone and helped people live a median of nearly two years, with 74.5% of BRAF V600 patients alive at one year and 48.3% alive at two years. Ongoing study monitoring did not identify any new safety signals. The company noted that an approval decision on Cotellic from the European Commission is expected before year end.
November 18, 2015
08:28 EDTRHHBYLeerink to hold a bus tour
Subscribe for More Information
08:11 EDTRHHBYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 17, 2015
07:34 EDTRHHBYOphthotech to hold a conference call
Subscribe for More Information
06:08 EDTRHHBYRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use